Biogen's stock jumps 42% after FDA staff says it has enough data to support approving Alzheimer's drug

The FDA agrees that results from Biogen's late-stage trial, study 302, are "highly persuasive" and the study is "capable of providing the primary contribution to a demonstration of substantial evidence of effectiveness of aducanumab."